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OBJECTIVES: Management of patients with bleeding
ulcers has evolved over the past ﬁve years, partly due to
the use of high dose intravenous, and more recently high
dose oral proton pump inhibitors (PPI’s). We compared
the cost effectiveness of the two. METHODS: Patients
with bleeding ulcers initially treated endoscopically for
high risk stigmata of re-bleeding were considered. The
model structure, deﬁned and validated by clinical experts,
evaluated rebleeding within 30 days. Probabilities were
determined from published literature. Charges and length
of stays (LOS) were obtained from a 20% random sample
of the NIS2000 (Nation-wide Inpatient Sample) adminis-
trative database. Pharmacological costs of high dose 
40mg Po BID ¥ 5 days and 80mg IV bolus followed by
8mg/hr ¥ 3 days were tabulated separately from the 
hospitalization costs. A third party payer perspective was
adopted; 2001 $US were used. Sensitivity and threshold
analyses were carried out. RESULTS: Mean LOS and
costs for patients admitted with uncomplicated and com-
plicated ulcer bleeding were 3 and 4.7 days, and $7993
and $11,802 respectively. Re-bleeding rates for patients
receiving oral or IV therapy were 7.3% and 5.9%. No
strategy dominated in base-case analysis: IV PPI cost
$14.90 more and was 1.44% more effective than oral PPI.
IV PPI became dominant when IV PPI re-bleeding rate
dropped below 5% or oral PPI re-bleeding rate rose over
8%. No differences in conclusions were noted over a wide
range of cost estimates. CONCLUSIONS: Based on pub-
lished data, high dose IV PPI for 3 days or oral proton
pump inhibition for ﬁve days were almost equivalent in
terms of outcomes with the IV form being slightly more
effective and more costly according to base case analysis
estimates. Prospective trials in Western patients are
required to conﬁrm the increased effectiveness, and sub-
sequently, the cost-effectiveness of high dose oral PPI.
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OBJECTIVES: To assess treatment patterns and associ-
ated health care cost in mebeverine users relative to
matched controls. METHODS: A matched case-control
study was performed using pharmacy data. Cases were
mebeverine users as proxy for IBS patients. Controls 
were non-mebeverine users and matched to cases by 
age, gender and pharmacy. Prevalence and incidence of
mebeverine use were estimated and concomitant drug 
use and hospitalisations were assessed in 3431 cases and
3431 controls. Concomitant drug use and hospitalisa-
tions was also assessed in a subgroup of 1222 users of
mebeverine and laxatives (proxy for constipation-IBS)
and their controls. RESULTS: Twelve per 1000 residents
were ever-dispensed mebeverine in 1998. One-third of
these mebeverine users used laxatives concomitantly.
Total concomitant drug use and hospitalisations were
increased in mebeverine users. The odds ratio for hospi-
talisations for gastrointestinal reasons was increased 
predominantly in mebeverine users with concomitant lax-
ative use (OR: 8.7; 95% CI = 4.3–17.3). Excess yearly
costs for all concomitant medications were €94 (95% 
CI = €79–€109) and for hospital admissions €120
(€74–€166) per mebeverine user. In mebeverine users with
concomitant laxative use these costs were €136 and €251
respectively. CONCLUSIONS: In the Netherlands only a
proportion of IBS patients is treated medically. In treated
patients, concomitant drug use and hospitalisations are
increased relative to matched controls. Medical resource
use and associated health care costs are particularly
increased in mebeverine users using laxatives, indicating
that constipation-predominant IBS is relative costly. The
total mean excess cost per patient per year is €480.
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OBJECTIVES: To estimate the incidence and cost of LC
in the US managed care population and determine if
patient characteristics affect the ratio of LC performed 
in inpatients versus outpatients. METHODS: MEDSTAT
MarketScanTM Commercial Claims and Encounters Data-
base (CCED) contains inpatient (IP) and outpatient (OP)
claims from over 2.5m people in 45 large U.S. employer-
sponsored plans and recorded 366,674 adult IP admis-
sions in 1999–2000. LC procedures were identiﬁed by
ICD-9-CM and CPT-4 codes. Annual LC incidence rate
was determined by percentage of persons age 18–65
undergoing LC within the average total CCED popula-
tion in 1999–2000. Proportion of IP LC among all admis-
sions was estimated. Proportions of IP and OP LC for all
patients and by age, gender, and primary diagnosis were
determined and compared by chi-square or Wilcoxon
tests. Cost of LC was estimated within study groups.
RESULTS: We identiﬁed 22,598 LC patients (IP 21.4%;
OP 78.6%). Average annual LC incidence rate was
0.85%. Approximately 1.32% of all hospital admissions
were for LC. 76.65% of LC patients were female. IP 
